Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer

The FDA approved daraxonrasib, a pan-RAS inhibitor drug, for metastatic pancreatic adenocarcinoma after prior systemic therapy, based on phase 3 RASolute 302 trial results showing a significant survival benefit over chemotherapy. Daraxonrasib uniquely targets the RAS ON state, effective across RAS mutations and wild-type tumors, expanding treatment options especially for patients intolerant to multi-agent chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.